495 related articles for article (PubMed ID: 28458525)
1. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
[TBL] [Abstract][Full Text] [Related]
2. Rivastigmine in vascular dementia.
Vincent S; Lane R
Int Psychogeriatr; 2003; 15 Suppl 1():201-5. PubMed ID: 16191241
[TBL] [Abstract][Full Text] [Related]
3. Rivastigmine in vascular dementia.
Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
Expert Opin Pharmacother; 2004 Jun; 5(6):1399-410. PubMed ID: 15163283
[TBL] [Abstract][Full Text] [Related]
4. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
Rösler M
Int J Clin Pract Suppl; 2002 Jun; (127):20-36. PubMed ID: 12139365
[TBL] [Abstract][Full Text] [Related]
7. Rivastigmine for subcortical vascular dementia.
Román GC
Expert Rev Neurother; 2005 May; 5(3):309-13. PubMed ID: 15938663
[TBL] [Abstract][Full Text] [Related]
8. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Ballard CG
Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
[TBL] [Abstract][Full Text] [Related]
9. Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment.
Adeowo FY; Oyetunji TP; Ejalonibu MA; Ndagi U; Kumalo HM; Lawal MM
Chem Biodivers; 2021 Nov; 18(11):e2100361. PubMed ID: 34547176
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
[TBL] [Abstract][Full Text] [Related]
11. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
12. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase.
Bullock R; Lane R
Curr Alzheimer Res; 2007 Jul; 4(3):277-93. PubMed ID: 17627485
[TBL] [Abstract][Full Text] [Related]
13. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Ogura H; Kosasa T; Kuriya Y; Yamanishi Y
Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):609-13. PubMed ID: 11256231
[TBL] [Abstract][Full Text] [Related]
14. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Bullock R
Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
[TBL] [Abstract][Full Text] [Related]
15. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients.
Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
Am J Alzheimers Dis Other Demen; 2003; 18(5):265-72. PubMed ID: 14569643
[TBL] [Abstract][Full Text] [Related]
16. Rivastigmine in subcortical vascular dementia: an open 22-month study.
Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
J Neurol Sci; 2002 Nov; 203-204():141-6. PubMed ID: 12417373
[TBL] [Abstract][Full Text] [Related]
17. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
18. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
Bullock R; Cameron A
Curr Med Res Opin; 2002; 18(5):258-64. PubMed ID: 12240787
[TBL] [Abstract][Full Text] [Related]
19. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
[TBL] [Abstract][Full Text] [Related]
20. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]